Диссертация (1154767), страница 15
Текст из файла (страница 15)
Apoprotein C-III: A review of its clinicalimplications. Clin Chim Acta. 2016;460:50-54.71.Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A.Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease. NEngl J Med. 2014;371(1):32-41.72.KamstrupPR,Tybjærg-HansenA,NordestgaardBG.ExtremeLipoprotein(a) Levels and Improved Cardiovascular Risk Prediction.
J Am CollCardiol. 2013;61(11):1146-1156.73.Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM.Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion ofhuman monocytic cells to endothelial cells. Circulation. 2006;113(5):691-700.74.Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ,Wenger NK. Effect of high-dose atorvastatin on hospitalizations for heart failure:subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115:576–583.75.Kivistö KT, Niemi M. Influence of Drug Transporter Polymorphisms onPravastatin Pharmacokinetics in Humans.
Pharm Res. 2007;24(2):239-247.76.Kluger M, Heeren J, Merkel M. Apoprotein A-V: An important regulator oftriglyceride metabolism. J Inherit Metab Dis. 2008;31(2):281-288.10077.Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinctstatins. Atherosclerosis. 2011; 215(1): 1-8.78.Kohli, Payal; Knowles, Joshua W; Sarraju, Ashish; Waters, David D;Reaven, Gerald. Metabolic Markers to Predict Incident Diabetes Mellitus in StatinTreated Patients (from the Treating to New Targets and the Stroke Prevention byAggressive Reduction in Cholesterol Levels Trials). The American Journal ofCardiology; New York118.9 (Nov 1, 2016): 1275-1281.79.Kostis W.
J. How Low an LDL-C Should We Go With Statin Therapy? CurrAtheroscler Rep, 2014, 16:388.80.Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB.Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 38(12):51-61.81.Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis andmanagement, Part 1. Mayo Clin Proc. 2009; 84(10): 917-38.82.Kwon SW, Lee BK, Hong B-K, et al. Prognostic significance of elevatedlipoprotein(a) in coronary artery revascularization patients.
Int J Cardiol.2013;167(5):1990-1994.83.Lamon-FavaS,DiffenderferMR,MarcovinaSM.Lipoprotein(a)metabolism. Curr Opin Lipidol. 2014;25(3):189-193.84.Larsson M, Vorrsjö E, Talmud P, Lookene A, Olivecrona G.Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement ofthe enzyme from lipid droplets. J Biol Chem. 2013;288(47):33997-34008.85.Laties AM, Shear CL, Lippa EA, et al. Expanded clinical evaluation oflovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeksof treatment with lovastatin. Am J Cardiol 1991; 67: 447–53.86.Lee SR, Prasad A, Choi Y-S, et al.
LPA Gene, Ethnicity, and CardiovascularEventsClinical Perspective. Circulation. 2017;135(3):251-263.87.Lee, K.H., Jeong, M.H., Kim, H.M., Ahn, Y., Kim, J.H., Chae, S.C., Kim,Y.J., Hur, S.H., Seong, I.W., Hong, T.J., Choi, D.H., Cho, M.C., Kim, C.J., Seung,K.B., Chung, W.S., Jang, Y.S., Rha, S.W., Bae, J.H., Cho, J.G., Park, S.J. Benefit101of early statin therapy in patients with acute myocardial infarction who haveextremely low low-density lipoprotein cholesterol.
J Am Coll Cardiol.2011;58:1664–1671.88.Leeper N, Ardehali R, deGoma E, Heidenreich P. Statin use in patients withextremely low low-density lipoprotein levels is associated with improved survival.Circulation. 2007; 116(6): 613-8.89.Li JH, Suchindran S, Shah SH, Kraus WE, Ginsburg GS, Voora D.SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levelsandclinicaleventsinpatientsfollowingcardiaccatheterization.Pharmacogenomics. 2015;16(5):449-458.90.Li S, Yang Y, Ouyang X, et al.
Associations of the APOC3 rs2854116 andrs2854117 polymorphisms with plasma APOC3 and lipid levels: a meta-analysis.Int J Clin Exp Med 2016;9(8):15972-985.91.Lin B, Huang Y, Zhang M, et al. Association between apolipoprotein C3 SstI, T-455C, C-482T and C1100T polymorphisms and risk of coronary heart disease.BMJ Open. - 2014. - 4(1).
- e004156.92.Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO.Apolipoprotein A-V-heparin interactions: implications for plasma lipoproteinmetabolism. J Biol Chem. 2005;280(27):25383-25387.93.Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role forproteoglycans in trapping, transferring, and internalizing. J Clin Invest.2007;117(1):1-5.94.Mahley RW, Rall SC. Apolipoprotein E: Far More Than a Lipid TransportProtein. Annu Rev Genomics Hum Genet. 2000;1(1):507-537.95.Mahley RW, Weisgraber KH, Huang Y.
Apolipoprotein E: structuredetermines function, from atherosclerosis to Alzheimer’s disease to AIDS. J LipidRes. 2009;50183-188.96.Malhotra A. Saturated fat is not the major issue. BMJ 2013; 347: f6340.10297.Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a):structure, pathophysiology and clinical implications. Arq Bras Cardiol.2014;103(1):76-84.98.Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants,and the risk of rhabdomyolysis. Pharmacogenet Genomics.
2011;21(5):280-288.99.Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identificationof Genetic Variants Associated With Response to Statin Therapy. ArteriosclerThromb Vasc Biol. 2009;29(9):1310-1315.100. Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of VeryLow-DensityLipoproteinandLow-DensityLipoproteinContainingApolipoprotein C-III and Not Other Small Apolipoproteins. Arterioscler ThrombVasc Biol.
2010;30(2):239-245.101. Miller M, Cannon CP, Murphy SA, et al. Impact of Triglyceride LevelsBeyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome inthe PROVE IT-TIMI 22 Trial. J Am Coll Cardiol. 2008;51(7):724-730.102. Nelbach L, Shu X, Konrad RJ, Ryan RO, Forte TM. Effect of apolipoproteinA-V on plasma triglyceride, lipoprotein size, and composition in geneticallyengineered mice. J Lipid Res.
2008;49(3):572-580.103. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ,Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I,Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect ofEvolocumab on Progression of Coronary Disease in Statin-Treated Patients: TheGLAGOV Randomized Clinical Trial. JAMA. 2016 Dec 13;316(22):2373-2384.104.
Nielsen SF, Nordestgaard BG. Negative statin-related news stories decreasestatin persistence and increase myocardial infarction and cardiovascular mortality:a nationwide prospective cohort study. Eur Heart J. 2016;37(11):908-916.105. Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A-V; apotent triglyceride reducer.
Atherosclerosis. 2011;219(1):15-21.103106. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin Therapy, LDLCholesterol, C-Reactive Protein, and Coronary Artery Disease. New Engl J Med2005; 352: 29-38.107. Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very importantpharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010;20(3):211-216.108. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different Effects ofSLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin andRosuvastatin. Clin Pharmacol Ther. 2007;82(6):726-733.109.
Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M.Polymorphism of the hepatic influx transporter organic anion transportingpolypeptide 1B1 is associated with increased cholesterol synthesis rate.Pharmacogenet Genomics. 2008;18(10):921-926.110. Pollex RL, Ban MR, Young TK, et al. Association between the -455T>Cpromoter polymorphism of the APOC3gene and the metabolic syndrome in amulti-ethnic sample. BMC Med Genet. 2007;8(1):80.111. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysisof genome-wide association studies of LDL cholesterol response to statins.
NatCommun. 2014;5:5068.112. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes withintensive-dose compared with moderate-dose statin therapy: a metaanalysis.JAMA. 2011; 305(24): 2556-64113. Preiss D, Tikkanen MJ, Welsh P, et al. Lipid-modifying therapies and risk ofpancreatitis: a meta-analysis. JAMA 2012; 308: 804–11.114. Prospective Studies Collaboration. Blood cholesterol and vascular mortalityby age, sex, and blood pressure: a meta-analysis of individual data from 61prospective studies with 55 000 vascular deaths. Lancet 2007; 370: 1829–39.115. Putzer G, Roetzheim R, Ramirez AM, et al.
Compliance withrecommendations for lipid management among patients with type 2 diabetes in anacademic family practice. J Am Board Fam Pract. 2004 Mar-Apr; 17(2): 101-7.104116. Qi L, Liu S, Rifai N, Hunter D, Hu FB. Associations of the apolipoproteinA1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in womenwith type 2 diabetes. Atherosclerosis. 2007;192(1):204-210.117.
Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor isnot required for normal catabolism of Lp(a) in humans. J Clin Invest.1995;95(3):1403-1408.118. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM,Jackson G, Braunwald E. Early and late benefits of high-dose atorvastatin inpatients with acute coronary syndromes: results from the PROVEIT-TIMI 22 trial.J Am Coll Cardiol 2005;46:1405–1410.119. Reiner Ž, De Backer G, Fras Z, et al.
Lipid lowering drug therapy in patientswith coronary heart disease from 24 European countries – Findings from theEUROASPIRE IV survey. Atherosclerosis. 2016;246:243-250.120. Richardson K, Schoen M, French B, et al. Statins and cognitive function: asystematic review. Ann Intern Med. 2013;159:688-697.121. Ridker P.M., Cannon C.P., Morrow D., et al. C-Reactive Protein Levels andOutcome after Statin Therapy. New Engl J Med,352:20-28,2005.122. Ridker PM, Hennekens CH, Stampfer MJ.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
